Literature DB >> 24610911

Neoadjuvant trials could speed up drug approvals.

Judy Peres.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24610911     DOI: 10.1093/jnci/dju072

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Authors:  T R Cottrell; E D Thompson; P M Forde; J E Stein; A S Duffield; V Anagnostou; N Rekhtman; R A Anders; J D Cuda; P B Illei; E Gabrielson; F B Askin; N Niknafs; K N Smith; M J Velez; J L Sauter; J M Isbell; D R Jones; R J Battafarano; S C Yang; L Danilova; J D Wolchok; S L Topalian; V E Velculescu; D M Pardoll; J R Brahmer; M D Hellmann; J E Chaft; A Cimino-Mathews; J M Taube
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

2.  Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).

Authors:  Changjun Wang; Yidong Zhou; Yan Lin; Feng Mao; Jinghong Guan; Xiaohui Zhang; Songjie Shen; Xuejing Wang; Yanna Zhang; Bo Pan; Ying Zhong; Li Peng; Xi Cao; Ru Yao; Xingtong Zhou; Chi Xu; Ying Xu; Qiang Sun
Journal:  BMC Cancer       Date:  2022-03-14       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.